Esperion has one ongoing Phase 3 trial for bempedoic acid: In 2016, we initiated a global cardiovascular outcomes trial (CVOT) – CLEAR Outcomes – with more than 14,000 patients in 32 countries, estimated to last nearly five years. CLEAR Outcomes is the first CVOT that specifically enrolled patients with statin intolerance, and is an event-driven, randomized, multicenter, double-blind, placebo-controlled trial designed to evaluate whether treatment with bempedoic acid reduces the risk of cardiovascular events. Based on estimated cardiovascular event rates, we expect the CLEAR Outcomes trial to conclude in the second half of 2022.
As part of Esperion’s commitment to transparency, summaries of clinical studies are available below. Please visit clinicaltrials.gov for more information on clinical trials.
Clinical Studies
Placeholder for no text
*Please Note: Esperion is subject to all applicable federal, state and/or local transparency laws and regulations related to the transfer of items of value such as educational items (e.g., journal articles) that may be provided to you in order to respond to your unsolicited request for medical information. Based on applicable laws and regulations, the value of any reportable transfer of value may be made publicly available.